Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 6, Issue 22
November 22 2022
Issue Cover

Table of Contents

CLINICAL TRIALS AND OBSERVATIONS

Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation
Clinical Trials & Observations
Mariam T. Nawas,Miriam Sanchez-Escamilla,Sean M. Devlin,Molly A. Maloy,Josel D. Ruiz,Craig S. Sauter,Sergio A. Giralt,Miguel-Angel Perales,Michael Scordo
View Articletitled, Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation
Supplemental data

HEALTH SERVICES AND OUTCOMES

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
Gilles Salles,Stephen J. Schuster,Martin Dreyling,Luca Fischer,John Kuruvilla,Piers E. M. Patten,Bastian von Tresckow,Sonali M. Smith,Ana Jiménez-Ubieto,Keith L. Davis,Carla Anjos,Jufen Chu,Jie Zhang,Chiara Lobetti Bodoni,Catherine Thieblemont,Nathan H. Fowler,Michael Dickinson,Joaquin Martínez-López,Yucai Wang,Brian K. Link
View Articletitled, Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

IMMUNOBIOLOGY AND IMMUNOTHERAPY

CD58 loss in tumor cells confers functional impairment of CAR T cells
Xin Yan,Deyun Chen,Xinran Ma,Yao Wang,Yelei Guo,Jianshu Wei,Chuan Tong,Qi Zhu,Yuting Lu,Yang Yu,Zhiqiang Wu,Weidong Han
View Articletitled, CD58 loss in tumor cells confers functional impairment of CAR T cells
Supplemental data
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
Carolina Schinke,Alexandra M. Poos,Michael Bauer,Lukas John,Sarah Johnson,Shayu Deshpande,Luis Carrillo,Daisy Alapat,Leo Rasche,Sharmilan Thanendrarajan,Maurizio Zangari,Samer Al Hadidi,Frits van Rhee,Faith Davies,Marc S. Raab,Gareth Morgan,Niels Weinhold
View Articletitled, Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
Supplemental data

LYMPHOID NEOPLASIA

Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma
Andrés J. M. Ferreri,Piera Angelillo,Federico Erbella,Chiara Cattaneo,Luisa Verga,Arben Lleshi,Bernardino Allione,Maurilio Ponzoni,Fabio Facchetti,Chiara Pagani,Marco Foppoli,Lorenza Pecciarini,Marianna Sassone,Sara Steffanoni,Elena Flospergher,Giuseppe Rossi,Michele Spina,Alessandro Re
View Articletitled, Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma
The outcome of older adults with classic Hodgkin lymphoma in British Columbia
Phoebe T. M. Cheng,Diego Villa,Alina S. Gerrie,Ciara L. Freeman,Graham W. Slack,Randy D. Gascoyne,Pedro Farinha,Jeffrey W. Craig,Brian Skinnider,Don Wilson,David W. Scott,Joseph M. Connors,Laurie H. Sehn,Kerry J. Savage
View Articletitled, The outcome of older adults with classic Hodgkin lymphoma in British Columbia
Supplemental data

MYELOID NEOPLASIA

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies
Clinical Trials & Observations
Amir T. Fathi,Haesook T. Kim,Robert J. Soiffer,Mark J. Levis,Shuli Li,Annette S. Kim,Alice S. Mims,Zachariah DeFilipp,Areej El-Jawahri,Steven L. McAfee,Andrew M. Brunner,Rupa Narayan,Laura W. Knight,Devon Kelley,AJ S. Bottoms,Lindsey H. Perry,Jonathan L. Wahl,Jennifer Brock,Elayne Breton,Vincent T. Ho,Yi-Bin Chen
View Articletitled, Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for <em>IDH2</em>-mutated myeloid malignancies
Supplemental data
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
Clinical Trials & Observations
Giulia Pianigiani,Andrea Gagliardi,Federica Mezzasoma,Francesca Rocchio,Valentina Tini,Barbara Bigerna,Paolo Sportoletti,Simona Caruso,Andrea Marra,Sara Peruzzi,Eleonora Petito,Giulio Spinozzi,Sharon Shacham,Yosef Landesman,Concetta Quintarelli,Paolo Gresele,Franco Locatelli,Maria Paola Martelli,Brunangelo Falini,Lorenzo Brunetti
View Articletitled, Prolonged XPO1 inhibition is essential for optimal antileukemic activity in <em>NPM1</em>-mutated AML
Supplemental data

THROMBOSIS AND HEMOSTASIS

Anticoagulation in pediatric cancer–associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr
Joseph S. Palumbo,Anthonie W. A. Lensing,Leonardo R. Brandão,Hélène L. Hooimeijer,Gili Kenet,Heleen van Ommen,Akos F. Pap,Madhurima Majumder,Dagmar Kubitza,Kirstin Thelen,Stefan Willmann,Martin H. Prins,Paul Monagle,Christoph Male
View Articletitled, Anticoagulation in pediatric cancer–associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr
Mutations of TFPI-binding exosites on factor VII cause bleeding phenotypes in factor VII deficiency
Karnsasin Seanoon,Panwajee Payongsri,Pornpun Vivithanaporn,Nongnuch Sirachainan,Ampaiwan Chuansumrit,Suradej Hongeng,Pansakorn Tanratana
View Articletitled, Mutations of TFPI-binding exosites on factor VII cause bleeding phenotypes in factor VII deficiency
Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia
Clinical Trials & Observations
Leonardo R. Brandão,Igor Tartakovsky,Manuela Albisetti,Jacqueline Halton,Lisa Bomgaars,Elizabeth Chalmers,Matteo Luciani,Paola Saracco,Judy Felgenhauer,Olga Lvova,Monika Simetzberger,Zhichao Sun,Lesley G. Mitchell,on behalf of the DIVERSITY and Secondary VTE Prevention Study Investigators
View Articletitled, Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia
Supplemental data

RESEARCH LETTERS

Megalobastic anemia, infantile leukemia, and immunodeficiency caused by a novel homozygous mutation in the DHFR gene
Taco W. Kuijpers,Andrica C. H. de Vries,Ester M. van Leeuwen,A.(Ton) A. M. Ermens,Saskia de Pont,Desirée E. C. Smith,Mirjam M. C. Wamelink,Arjen R. Mensenkamp,Marcel R. Nelen,Hana Lango Allen,Steven T. Pals,Berna H. B. Beverloo,Hidde H. Huidekoper,Anja Wagner,on behalf of the NIHR BioResource Study Group
View Articletitled, Megalobastic anemia, infantile leukemia, and immunodeficiency caused by a novel homozygous mutation in the <em>DHFR</em> gene
Introduction of an ancient founder glycoprotein VI mutation into the Chilean population
Amanda Dalby,Diego Mezzano,José Rivera,Steve P. Watson,Neil V. Morgan
View Articletitled, Introduction of an ancient founder glycoprotein VI mutation into the Chilean population
More to voxelotor than meets the eye?
Robert C. Bovino,Allan C. Jackson,Frank A. Ferrone
View Articletitled, More to voxelotor than meets the eye?
Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1–antibody-drug conjugate
Thao Tang,Quy Le,Sommer Castro,Laura Pardo,Cyd Nourigat McKay,LaKeisha Perkins,Jenny Smith,Danielle Kirkey,Cristina Abrahams,Kristin Bedard,Arturo Molina,Lisa Eidenshinck Brodersen,Michael R. Loken,Katherine Tarlock,Soheil Meshinchi,Keith R. Loeb
View Articletitled, Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1–antibody-drug conjugate
Supplemental data

ERRATA

Chari A, Cho HJ, Dhadwal A, et al. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Adv. 2017;1(19):1575-1583.
View Articletitled, Chari A, Cho HJ, Dhadwal A, et al. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. <em>Blood Adv.</em> 2017;1(19):1575-1583.
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6):1695-1705.
View Articletitled, Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. <em>Blood Adv.</em> 2021;5(6):1695-1705.
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.
View Articletitled, Smith CC, Levis MJ, Perl AE, et al. Molecular profile of <em>FLT3</em>-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. <em>Blood Adv.</em> 2022;6(7):2144-2155.
All Issues

Advertisement intended for health care professionals

Time to revisit reduced-dose radiotherapy for PCNSL?
Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.
Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals